Items and frequency of regular inspections required during treatment with Sotolaxib (AMG 510)

During treatment with Sotorasib (AMG 510), regular examinations are a key link to ensure efficacy and safety. As an important targeted drug for KRAS G12C mutated non-small cell lung cancer, sotoraxib has a significant effect in improving disease control rate. However, during use, it may cause adverse reactions such as abnormal liver function, gastrointestinal discomfort, and fatigue. Therefore, a series of examinations are needed to detect and deal with problems early to ensure the continuity and effectiveness of treatment.

First of all, liver function test is one of the most important monitoring items. Baseline testing should be performed before medication, including ALT, AST, total bilirubin and other indicators. After the start of treatment, it is recommended to review every 2 weeks in the first month, and then once a month or follow the doctor's individual arrangement. Sotorracib may cause an increase in liver enzymes. If obvious abnormalities are found during monitoring, the dose needs to be adjusted or the medication suspended according to the situation to avoid the progression of liver damage.

Secondly, imaging examinations are used for efficacy evaluation and disease tracking. CTCT or MRI is usually done before treatment as a baseline, and then reviewed every 6–8 weeks to assess changes in tumor volume, the emergence of new lesions or signs of drug resistance. If the patient's symptoms worsen or new clinical manifestations occur during treatment, the doctor may also arrange imaging examinations in advance to ensure that changes in the condition can be detected and dealt with in a timely manner.

Finally, routine blood and biochemical tests are required, such as blood routine, renal function, electrolytes, blood sugar, and urine routine, etc. In the early stage, it is recommended to check once every 2–4 weeks. Later, when the condition is stable, it can be extended to once every 1–2 months. These examinations help to comprehensively assess the patient's tolerance to drugs and promptly detect potential problems such as anemia, infection risk, and electrolyte imbalance. During the treatment period, patients should strictly follow the doctor's review plan and avoid reducing the frequency of examinations or delaying follow-up visits, so as to ensure the stability and long-term benefits of treatment.

Reference materials:https://www.drugs.com/